Provisional Conference Programme | Monday 28th June 2021
Registration, Posters Set-Up & Opening Remarks
SESSION 1:
OPENING PLENARY SESSION
Moderator: To be confirmed
KEYNOTE:
‘Pushing the envelope of HIV-1 vaccine design’
Richard Wyatt
(Scripps Research Institute, La Jolla, California, USA)
KEYNOTE:
‘Conventional and unconventional VLP based strategies for development of HIV vaccines’
Bryce Chackerian1, Alemu Mogus1, Julianne Peabody1, Larance Ronsard3, David Peabody1, Moriya Tsuji2 and Daniel Lingwood3
(1 University of New Mexico School of Medicine, Albuquerque, New Mexico, USA; 2 Aaron Diamond AIDS Research Center, New York, USA; 3 The Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA)
KEYNOTE:
‘A next generation Alzheimers vaccine’
Martin Bachmann
(University of Bern, Bern, Switzerland)
Lunch Break & Posters
SESSION 2:
DESIGN/DEVELOPMENT/PRODUCTION
Moderator: To be confirmed
‘VLPs of ssRNA phages: Diversity, strucure and applications in vaccine development’
Kaspars Tars
(University of Latvia, Riga, Latvia)
‘Design of hepatitis B virus-like particles (VLPs) to optimise immunisation outcomes for preventative or therapeutic applications’
Hans Netter
(Peter Doherty Institute, Melbourne, Victoria, Australia)
‘A strategy for the design of genetically thermo-stabilised, immunogenic poliovirus empty capsids for use as VLP vaccines’
Helen Fox, Sarah Knowlson, Philip Minor and Andrew J. Macadam
(Division of Virology, National Institute for Biological Standards and Control, South Mimms, Potters Bar, UK)
Tea Break & Posters
SESSION 3:
VLP VACCINES
Moderator: To be confirmed
‘VLP-based vaccines for cardiovascular disease’
Alexandra Fowler1, Erin Crossey1, Maureen Sampson2, Marcelo Amar2, John Schiller3, Koen Van Rompay4, Alan Remaley2 and Bryce Chackerian1
(1 University of New Mexico School of Medicine, Albuquerque, New Mexico, USA; 2 NIH/NHLBI, Bethesda, Maryland, USA; 3 NIH/NCI, Bethesda, Maryland, USA; 4 California Regional Primate Center, Davis, California, USA)
‘Liposome-adjuvanted Self-Assembling Protein Nanoparticles (SAPN) for HIV-1 Vaccine Development’
Zoltan Beck
(US Military HIV Research Program (MHRP), Laboratory of Antigen and Adjuvant Research, Walter Reed Army Institute of Research (WRAIR), Silver Spring, Maryland, USA)
‘Exploiting Pichia pastoris for production of a VLP vaccine against poliomyelitis’
Lee Sherry1, Keith Grehan1, Helen Fox2, Mohammad W. Bahar3, Elizabeth E. Fry3, David I. Stuart3, Andrew J. Macadam2, David J. Rowlands1
and Nicola J. Stonehouse1
(1 School of Molecular and Cellular Biology, University of Leeds, Leeds, UK; 2 Division of Virology, National Institute for Biological Standards and Control, South Mimms, Potters Bar, UK; 3 Division of Structural Biology, University of Oxford, Oxford, UK)
